Few studies have investigated the PD of oxaliplatin during HIPEC. These studies use PK/PD models to find associations between PK parameters and PD toxicitiesof the treatment. It has been demonstrated that HIPEC-induced neutropenia largely depends on the duration of the HIPEC procedure and the oxaliplatin concentration in the perfusate, which is related to systemic concentrations.It has been predicted that each 400 mg/l increase in initialoxaliplatin concentration causes a 28% decrease in the